About Myonexus Therapeutics
Myonexus Therapeutics is a Healthcare company based in Columbus (United States) founded in 2017 by Michael Triplett, and was acquired by Sarepta in May 2018. Clinical stage gene therapy company developing treatments for Limb-girdle muscular dystrophy (LGMD). Myonexus Therapeutics has raised $2.5 million across 1 funding round from investors including Sarepta Therapeutics, CincyTech and Rev1 Ventures. Its chief executive, as recorded, is Michael Triplett. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Insitro, BridgeBio and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
Myonexus Therapeutics was founded in 2017 in Columbus, United States, focusing on the gene therapy sector. Treatments for Limb-girdle muscular dystrophy types 2D, 2B, 2E, 2L, and 2C are being advanced, with research based at Nationwide Childrens Hospital. The lead candidate MYO-102, targeting alpha-sarcoglycan for LGMD2D, is in Phase 12a trials. FDA approval has been granted for Phase 12a trials of MYO-101 for LGMD2E via systemic IV delivery.
- Headquarters Columbus, United States
- Founders Michael Triplett
- Stage Acquired
- SectorsHealthcare
- Website myonexustx.com
- Social LinkedIn X
- Acquired by Sarepta (May 2018)
- Total Equity Funding$2.5M (USD)
in 1 rounds
- Latest Funding Round$2.5M (USD), Seed
Dec 2017
- InvestorsSarepta Therapeutics
& 4 more
- Acquired bySarepta
(May 2018)
Funding Insights of Myonexus Therapeutics
Myonexus Therapeutics has successfully raised a total of $2.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $2.5 million completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.5M
- Total Rounds 1
- Last Round Seed — $2.5M
- First Round $2.5M
(Dec 2017)
- Investors Count 4
All 1 funding rounds of Myonexus Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2017 | $2.5M | Seed | – | – |
5 investors in total: 5 institutional.
Investors in Myonexus Therapeutics
Myonexus Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Sarepta Therapeutics, CincyTech and Rev1 Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CincyTech is engaged in venture capital investments for innovative startups. | cincytechusa.com | Cincinnati, USA | ||
Startup Studio building companies in the US & Europe and Angel Network for Ohio based companies | rev1ventures.com | Columbus, United States | ||
| jain-foundation.org | ||||
RNA-targeted therapeutics are developed for rare and infectious diseases. | 1980 | sarepta.com | Cambridge, United States |
Investor details for Myonexus Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Myonexus Therapeutics
1 people are tracked at Myonexus Therapeutics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Michael Triplett | Co-Founder & CEO | Leadership |
Complete people profiles for Myonexus Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Myonexus Therapeutics
3 dated milestones of Myonexus Therapeutics across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Myonexus Therapeutics is founded.
- Funding First funding round of $2.5M.
- Exit Acquired by Sarepta.
Competitors of Myonexus Therapeutics
Myonexus Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of Myonexus Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Myonexus Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Myonexus Therapeutics
Complete news archive for Myonexus Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Myonexus Therapeutics
Myonexus Therapeutics was founded in 2017.
Myonexus Therapeutics is headquartered in Columbus, United States. It is registered at Columbus, Ohio, United States.
Michael Triplett is the CEO of Myonexus Therapeutics, as recorded in our data. They have also founded this company.
Myonexus Therapeutics is a funded company, having raised a total of $2.5M across 1 funding round to date. The company's 1st funding round was a Seed of $2.5M, raised on Dec 2017.
Myonexus Therapeutics was founded in 2017 in Columbus, United States, focusing on the gene therapy sector. Treatments for Limb-girdle muscular dystrophy types 2D, 2B, 2E, 2L, and 2C are being advanced, with research based at Nationwide Childrens Hospital. The lead candidate MYO-102, targeting alpha-sarcoglycan for LGMD2D, is in Phase 12a trials. FDA approval has been granted for Phase 12a trials of MYO-101 for LGMD2E via systemic IV delivery.
Myonexus Therapeutics's top competitors include BridgeBio, Forge Biologics and Insitro.
Myonexus Therapeutics has 5 investors. Key investors include Sarepta Therapeutics, CincyTech, Rev1 Ventures, Jain Foundation, and Gfbonlus.
Yes. Myonexus Therapeutics was acquired by Sarepta in May 2018.